Invitrogen

DMRT2 Polyclonal Antibody

8个已发表图片

3 篇参考文献

查看其他6个DMRT2抗体

抗体检测数据 (2)
已发表图片 (8)

DMRT2 Antibody in Immunohistochemistry (IHC)

DMRT2 Antibody in Immunohistochemistry (IHC)

图: 1 / 10

DMRT2 Antibody (PA5-41694) in IHC

Immunohistochemistry analysis of human kidney tissue using an anti-DMRT2 polyclonal antibody (Product # PA5-41694).

DMRT2 Antibody in Immunohistochemistry (IHC)

DMRT2 Antibody in Western Blot (WB)

DMRT2 Antibody in Western Blot, Immunohistochemistry (Paraffin) (WB, IHC (P))

DMRT2 Antibody in Immunohistochemistry (IHC)

DMRT2 Antibody in Western Blot, Immunohistochemistry (WB, IHC)

DMRT2 Antibody in Western Blot (WB)

DMRT2 Antibody in Western Blot (WB)

DMRT2 Antibody in Western Blot (WB)

DMRT2 Antibody in Western Blot (WB)

DMRT2 Antibody in Western Blot (WB)

Product Image Gallery

DMRT2 Antibody in Immunohistochemistry (IHC) — Immunohistochemistry analysis of human kidney tissue using an anti-DMRT2 polyclonal antibody (Product # PA5-41694).

DMRT2 Antibody in Western Blot (WB) — Western blot analysis of human HepG2 cell lysate using an anti-DMRT2 polyclonal antibody (Product # PA5-41694).

DMRT2 Antibody in Western Blot, Immunohistochemistry (Paraffin) (WB, IHC (P)) — Figure 5 DMRT2 directly interacts with FXR. (A) Protein-protein interaction analysis showing proteins that might interact with DMRT2. (B) The protein levels of FXR in IR adipocytes and IF adipocytes were examined using immunoblotting. (C) IR adipocytes were transfected with DMRT2 OE or sh-DMRT2 and examined for the protein levels of FXR by immunoblotting. (D) The interaction between DMRT2 and FXR was examined using IF staining. Green fluorescence indicated DMRT2. Red fluorescence indicated FXR. (E, F) The interaction between DMRT2 and FXR was examined using the co-IP assay. (G) 3T3-L1 cells were co-transfected with DMRT2 overexpression vector and GLUT4 promoter luciferase reporter vector. Then, the luciferase activity was measured. * P < 0.05, ** P < 0.01, compared with the control or vector group; ## P < 0.01, compared sh-NC with the sh-DMRT2 group.

DMRT2 Antibody in Immunohistochemistry (IHC) — In-vivo effects of DMRT2 in an insulin-resistant mouse model. The insulin-resistant model was established in mice as described. DMRT2 overexpression was achieved in control or model mice by injecting lentivirus containing DMRT2 OE. (A, B) Glucose tolerance test (GTT) and insulin tolerance test (ITT) were performed on mice as described and the area under curve (AUC) was calculated for each group. (C, D) Mice body weight and epididymal fat weight were examined. (E, H) The mRNA expression of TNF-alpha, IL-6, and DMRT2 in epididymal fat tissues was examined using qRT-PCR. (F) The histopathological characteristics of epididymal fat tissues were examined using H&E staining. (G) The levels of DMRT2 in epididymal fat tissues were examined using immunohistochemical (IHC) staining. ** P < 0.01, compared with the normal group; # P < 0.05, ## P < 0.01, compared Lv-Vector+HFD with the Lv-DMRT2 OE+HFD group.

DMRT2 Antibody in Western Blot, Immunohistochemistry (WB, IHC) — Figure 2 DMRT2 reduced inflammation and increased white adipose browning in the insulin-resistant mouse model. (A) The protein level of DMRT2 in epididymal fat tissues was examined using immunoblotting. (B) The protein levels of TNF-alpha and IL-6 in epididymal adipose tissues were examined using ELISA. (C) The macrophage infiltration was determined using IHC staining for F4/80. (D, E) The brown adipocytes in epididymal adipose tissues were determined using IHC staining and immunoblotting for UCP-1. ** P < 0.01, compared with the normal group; ## P < 0.01, compared Lv-Vector+HFD with the Lv-DMRT2 OE+HFD group.

DMRT2 Antibody in Western Blot (WB) — Figure 3 DMRT2 is downregulated in insulin-resistant adipocyte model. (A) 3T3-L1 preadipocytes were induced toward adipogenesis and the formation of lip droplets in preadipocytes and adipocytes was confirmed using oil O red staining. (B) The mRNA expression levels of Fabp4 and PPARgamma in preadipocytes and adipocytes were examined using qRT-PCR. Then, the insulin-resistant adipocyte model was established in differentiated adipocytes as described and examined for Fabp4 and PPARgamma mRNA levels (C) , glucose uptake ability (D) , and triglyceride content (E) ; cellular membrane-located GLUT4 levels in control or insulin-resistant (IR) adipocytes by immunofluorescent (IF) staining (F) ; membrane protein levels of GLUT4 in control or IR adipocytes by immunoblotting (G) ; the protein levels of Akt and p-Akt in control or IR adipocytes by immunoblotting (H) ; the mRNA expression of TNF-alpha and IL-6 in control or IR adipocytes by qRT-PCR (I) ; the secretion levels of TNF-alpha and IL-6 in control or IR adipocytes by ELISA (J) ; and the protein levels of DMRT2 in control or IR adipocytes by immunoblotting (K) . * P < 0.05, ** P < 0.01.

DMRT2 Antibody in Western Blot (WB) — In-vitro effects of DMRT2 on IR adipocytes. (A) DMRT2 overexpression or knockdown was achieved in adipocytes by transducing DMRT2-overexpressing vector (DMRT2 OE) or small interference RNA for DMRT2 (sh-DMRT2). The overexpression or knockdown of DMRT2 was confirmed using immunoblotting. Then, IR adipocytes were transfected with DMRT2 OE or sh-DMRT2 and examined for glucose uptake ability (B) ; protein levels of GLUT4 by immunoblotting (C) ; the protein levels of Akt and p-Akt by immunoblotting (D) ; and the mRNA expression of TNF-alpha and IL-6 in IR adipocytes by qRT-PCR (E) . * P < 0.05, ** P < 0.01, compared with the vector group; ## P < 0.01, compared sh-NC with the sh-DMRT2 group.

DMRT2 Antibody in Western Blot (WB) — Dynamic effects of DMRT2 and FXR on adipocyte resistance to insulin. IR adipocytes were co-transfected with DMRT2 OE and sh-FXR and examined for the protein levels of DMRT2 and FXR by immunoblotting (A) ; glucose uptake ability (B) , triglyceride content (C) , and the protein levels of GLUT4 by immunoblotting (D) ; the protein levels of Akt and p-Akt by immunoblotting (E) ; and the mRNA expression of TNF-alpha and IL-6 in control or IR adipocytes by qRT-PCR (F) . * P < 0.05, ** P < 0.01, compared with the Vector+sh-NC group; # P < 0.05, ## P < 0.01, compared Vector+sh-FXR with the DMRT2 OE+sh-FXR group.

DMRT2 Antibody in Western Blot (WB) — Published figure using DMRT2 polyclonal antibody (Product # PA5-41694) in Western Blot

DMRT2 Antibody in Western Blot (WB) — Published figure using DMRT2 polyclonal antibody (Product # PA5-41694) in Western Blot

产品信息

PA5-41694

应用

建议稀释比

已发表文章

免疫印迹 (WB)

1.25 µg/mL

查看1篇已发表文章 1篇已发表文章

免疫组化 (IHC)

5 µg/mL

查看1篇已发表文章 1篇已发表文章

免疫组化（石蜡） (IHC (P))

-

查看1篇已发表文章 1篇已发表文章

产品规格

已发表种属

Not Applicable

宿主/亚型

Rabbit / IgG

分类

Polyclonal

类型

Antibody

抗原

Synthetic peptide directed towards the N-terminal of human DMRT2 (aa 3-52).

查看免疫原

偶联物

Unconjugated Unconjugated Unconjugated

形式

Liquid

浓度

1 mg/mL

保存条件

-20° C, Avoid Freeze/Thaw Cycles

运输条件

Wet ice

AB_2576311

产品详细信息

Peptide sequence: DPQAGSAAGD WEIDVESLEL EEDVCGAPRS TPPGPSPPPA DGDCEDDEDD

Sequence homology: Human: 100%; Rabbit: 86%

靶标信息

Gonadal dysgenesis in 9p-deleted individuals might be due to combined hemizygosity of DMRT1 and DMRT2.

仅用于科研。不用于诊断过程。未经明确授权不得转售。

Product References

DMRT2 Interacts With FXR and Improves Insulin Resistance in Adipocytes and a Mouse Model.

Frontiers in endocrinology

Tao J,Yu XL,Yuan YJ,Shen X,Liu J,Gu PP,Wang Z,Ma YT,Li GQ

Published figure using DMRT2 polyclonal antibody (Product # PA5-41694) in Immunohistochemistry

Fri Apr 22 00:00:00 UTC 2022

DMRT2 Interacts With FXR and Improves Insulin Resistance in Adipocytes and a Mouse Model.

Frontiers in endocrinology

Tao J,Yu XL,Yuan YJ,Shen X,Liu J,Gu PP,Wang Z,Ma YT,Li GQ

Published figure using DMRT2 polyclonal antibody (Product # PA5-41694) in Immunohistochemistry

Fri Apr 22 00:00:00 UTC 2022

DMRT2 Interacts With FXR and Improves Insulin Resistance in Adipocytes and a Mouse Model.

Frontiers in endocrinology

Tao J,Yu XL,Yuan YJ,Shen X,Liu J,Gu PP,Wang Z,Ma YT,Li GQ

Published figure using DMRT2 polyclonal antibody (Product # PA5-41694) in Immunohistochemistry

Fri Apr 22 00:00:00 UTC 2022